NIFTYNXT50 Archives - Page 2 of 11

TORNTPHARMA – Torrent Pharmaceuticals – Q4 FY26 Financial Results – 22-May-26

Torrent Pharma’s FY26 vaulted revenues past ₹13,900 Cr via acquisition, but net debt/EBITDA ~2.9x and ₹24,280 Cr intangibles suppress PAT. Core remains resilient with ₹2,346 Cr FCF and ~31% EBITDA margins. Re‑rating hinges on brand revenue scaling faster than amortisation; watch receivables and finance costs.

1–2 minutes

🔍 Observations

Topline

Revenue from ops grew 21.4% YoY (₹11,516 Cr → ₹13,980 Cr), reflecting the step-up from an acquired business consolidating into FY26 numbers.
Q4FY26 printed ₹4,197 Cr — +41.8% YoY and +27.1% QoQ — the sharpest quarterly outturn, indicating the full consolidation effect landed in Q4.
Other income turned negative in FY26 (–₹94 Cr vs +₹23 Cr), reflecting forex and hedging losses that clipped reported total income.

Bottomline

Net profit grew 11.9% YoY (₹1,911 Cr → ₹2,138 Cr), well below revenue growth — margin dilution from acquisition-linked D&A and finance costs.
Q4FY26 net profit collapsed to ₹364 Cr vs ₹498 Cr in Q4FY25 (–26.9% YoY), driven by ₹236 Cr finance costs, ₹508 Cr D&A, and ₹66 Cr exceptional charges in a single quarter.
Effective tax rate improved to 25.6% (from 28.5%), providing partial offset; without this, PAT growth would have been thinner still.

Margins

EBITDA margin contracted ~100 bps to 31.3% (FY26) from 32.3% (FY25) — operating leverage partly absorbed by employee cost growth of 21.2% YoY.
Net profit margin compressed 130 bps to 15.3%, squeezed by D&A surging 40.8% and finance costs up 52.8%.
Q4FY26 EBITDA margin held at 31.9% (vs 32.0% in Q4FY25) — the operational core is stable; below-EBITDA lines are where the dilution originates.

Growth Trajectory

Organic revenue growth is likely sub-15%; the headline 21.4% is acquisition-inflated — normalisation will depend on how fast the acquired portfolio integrates.
EPS grew 13.2% (₹56.47 → ₹63.92) despite no equity dilution — share count unchanged at 169.23 Cr shares — all growth is earnings-driven on the legacy base.
D&A will remain elevated for multiple years as ₹24,280 Cr of intangible assets amortise; this is the single biggest structural drag on reported PAT growth.

GAIL – GAIL India Ltd – Q4 FY26 Financial Results – 21-May-26

GAIL’s FY26 shows regulated transmission/city gas resilience but commodity fragility — gas marketing spread compression and petrochemical losses erased ₹6,000 Cr EBIT. Capex builds pipeline/tariff upside, but near‑term hinges on spread normalization and petrochem breakeven. Dividend risk: FY26 payouts exceeded FCF via borrowing, unsustainable without FY27 earnings recovery.

1–2 minutes

🔍 Observations

Topline

Revenue from operations flat YoY at ₹1,42,094 Cr vs ₹1,42,290 Cr (-0.1%) — Natural Gas Marketing dominance (~₹1,44,713 Cr gross) masks transmission and city gas growth beneath a stagnant headline.
Q4FY26 revenue at ₹35,705 Cr declined 2.3% YoY vs Q4FY25’s ₹36,549 Cr, with Natural Gas Marketing segment bearing most of the pressure.
City Gas segment bucked the trend — full-year revenue grew 22.3% YoY (₹6,052 Cr → ₹7,401 Cr), the strongest growth vector across all segments.

Bottomline

Net profit collapsed 39.2% YoY (₹12,463 Cr → ₹7,582 Cr); FY25 included ₹2,440 Cr exceptional income, but even on comparable pre-exceptional basis PBT fell 39.6% (₹13,655 Cr → ₹9,725 Cr).
Q4FY26 PAT at ₹1,481 Cr fell 40.9% vs Q4FY25’s ₹2,506 Cr — deterioration accelerated in Q4, not just a full-year averaging effect.
Petrochemicals swung to a deep loss of ₹1,410 Cr EBIT in FY26 vs near-breakeven ₹(41) Cr in FY25; Natural Gas Marketing EBIT crashed 59.3% (₹7,795 Cr → ₹3,175 Cr).

Margins

EBITDA proxy (PBT + Finance Cost + Depreciation, before JV share): ₹9,725 + ₹964 + ₹3,835 = ₹14,524 Cr on revenue of ₹1,42,094 Cr → EBITDA margin ~10.2% vs FY25: ₹13,655 + ₹740 + ₹3,799 = ₹18,194 Cr on ₹1,42,290 Cr → 12.8%. 260 bps margin compression YoY.
Net profit margin: 5.3% in FY26 vs 8.8% in FY25 — a 350 bps erosion driven by gas marketing spread compression and petrochemical losses.
Other expenses surged 24.6% YoY (₹8,515 Cr → ₹10,613 Cr) — a cost-side deterioration that compounds the revenue-side weakness.

Growth Trajectory

Natural Gas Transmission (the high-quality, regulated annuity segment) grew EBIT 13.5% YoY (₹5,488 Cr → ₹6,229 Cr) — the one structural bright spot.
JV/associate profit contribution held flat at ~₹1,504 Cr — a stable but non-growing buffer.
EPS fell from ₹18.93 to ₹11.53 (-39.1%) with no equity dilution — the decline is purely earnings-driven, not structural.

MOTHERSON – Samvardhana Motherson International – Q4 FY26 Financial Results – 20-May-26

Motherson’s FY26 shows 10.6% EBITDA growth, OCF nearly doubling, and Q4 margin at 11.1% — clearest inflection yet. PAT flat from exceptions, but underlying trajectory healthy. Re‑rating hinges on sustaining >10% EBITDA margins; near‑term headwinds are rising capex, WC build, and EPS dilution.

1–2 minutes

🔍 Observations

Topline

Revenue from operations hit ₹1,26,104 Cr in FY26, up 10.9% YoY (from ₹1,13,663 Cr), driven by broad-based segment growth.
Q4FY26 revenue surged to ₹34,309 Cr, up 17.0% YoY from ₹29,317 Cr — strongest quarterly print of FY26.
Emerging Businesses was the standout, growing 49.5% YoY (₹11,418 Cr → ₹17,072 Cr at segment level); Integrated Assemblies grew 9.2%.

Bottomline

FY26 PAT at ₹4,086 Cr, marginally down from ₹4,146 Cr in FY25 — despite 10.9% revenue growth, exceptional charges of ₹414 Cr dragged net profit.
Q4FY26 PAT jumped 40% YoY (₹1,115 Cr → ₹1,562 Cr), signaling strong exit-quarter momentum.
Pre-exceptional PBT grew 6.5% YoY (₹5,261 Cr → ₹5,624 Cr); full-year PAT suppression is entirely attributable to the ₹414 Cr exceptional line.

Margins

FY26 EBITDA: ₹12,033 Cr vs ₹10,877 Cr in FY25 — EBITDA margin expanded to 9.5% from 9.6% on reported revenue (flat), but EBITDA grew 10.6% in absolute terms.
Q4FY26 EBITDA margin: ₹3,805 Cr on ₹34,309 Cr revenue = 11.1%, vs 9.1% in Q4FY25 — 200bps sequential and YoY expansion.
Operating margin (per KPIs): Q4FY26 at 6.9% vs 4.7% in Q4FY25; FY26 full year flat at 5.2% — Q4 outperformance is a meaningful inflection signal.

Growth Trajectory

FY26 revenue CAGR base is now ₹1.26L Cr; Motherson has a stated $36B revenue target — still significant headroom to grow.
Employee costs grew 10.9% YoY (₹28,387 Cr → ₹31,478 Cr), in line with revenue — no labour cost deleverage yet.
Finance costs fell 13.7% YoY (₹1,882 Cr → ₹1,624 Cr) despite higher borrowings — reflects QIP proceeds deployed and debt mix optimization.

MUTHOOTFIN – Muthoot Finance – Q4 FY26 Earnings Call – 14-May-26

Muthoot Finance’s topline growth remains robust, but margins face pressure from yield normalization and rising costs; bottomline resilience hinges on NPA recoverability and subsidiary scaling.

1–2 minutes

Also see: MUTHOOTFIN – Muthoot Finance – Q4 FY26 Financial Results – 14-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

AUM grows 12–15% with yields stabilizing at 19–20%. Competitive pressure caps margin expansion, but NPA recoverability (58% LTV) limits downside. Branch expansion supports long-term volume growth.

BOSCHLTD – Bosch Limited – Q4 FY26 Financial Results – 20-May-26

Bosch India’s FY26 confirms a cash‑rich industrial compounding low‑mid teens revenue, with ~17% underlying earnings growth post divestiture gain. Risks: commodity cost pressures, receivables velocity, and tax normalization. Overcapitalized balance sheet (₹83,797 Mio treasury, negligible debt) makes capital allocation discipline the key re‑rating driver.

1–2 minutes

🔍 Observations

Topline

Revenue grew 10.8% YoY to ₹200,347 Mio in FY26, crossing the ₹200 Bn milestone; Q4FY26 accelerated to 13.3% YoY, signalling momentum building into year-end.
Automotive products — 88.9% of net revenues — drove growth at 14.5% YoY (₹178,074 Mio vs ₹155,489 Mio); Consumer goods grew a modest 6.4%.
“Others” segment revenue collapsed 49.5% YoY (₹8,486 Mio to ₹4,285 Mio), reflecting the deliberate divestiture of specified businesses rather than organic decline.

Bottomline

Reported PAT jumped 37.6% YoY to ₹27,700 Mio, but ₹5,560 Mio in pre-tax exceptional gains (divestiture proceeds) inflate this; adjusted PAT grew ~16.9% to ~₹23,530 Mio.
EPS (basic) rose to ₹940.27 from ₹683.25 — reported basis; underlying earnings quality is solid even after stripping out the exceptional.
Q4FY26 PAT of ₹5,685 Mio grew 2.7% YoY and 6.8% QoQ, a clean quarter with no exceptional items.

Margins

EBITDA margin (excl. exceptional) expanded marginally to 17.5% from 17.3% — a tight band suggesting cost discipline offset input cost pressures.
Automotive EBIT margin held flat at 14.4% YoY despite 14.5% revenue growth — volume-driven profit expansion with no margin dilution.
Q4FY26 EBITDA margin contracted to 16.9% vs 18.0% in Q4FY25, partly from higher raw material costs (Q4 RM+traded goods: ₹35,710 Mio vs ₹30,242 Mio in Q4FY25, +18.1%).

Growth Trajectory

Three-year revenue CAGR context: crossing ₹200 Bn on a consolidated basis reflects steady compounding in the mid-teens in Automotive — structurally tied to India’s vehicle production cycle.
Automotive EBIT grew 13.8% YoY (₹22,467 Mio to ₹25,570 Mio) in line with segment revenue — consistent conversion, no margin surprises.
Consumer goods EBIT grew 7.6% (₹1,130 Mio to ₹1,216 Mio) — low-margin, slow-growth segment; EBIT margin at 6.6%, unchanged from 6.5% prior year.

TVSMOTOR – TVS Motor Company – Q4 FY26 Earnings Call – 13-May-26

TVS Motor’s topline growth hinges on export momentum and EV scaling, while margins depend on commodity offsets and premium mix; structural tailwinds (capacity, R&D, partnerships) outweigh cyclical risks if execution holds.

1–2 minutes

Also see: TVSMOTOR – TVS Motor Company – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Commodity inflation at 3–5%, supply chain resolves by H1 FY27, EV penetration at 8–9%, export growth at 15–20%.
Outcome: Revenue grows 10–12% YoY, EBITDA margin sustains at 13%, and EV revenue reaches ~INR 7,000 crore. Capex execution on track; margin stability via price hikes and mix.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

Zydus’ FY26 shows EBITDA margin expansion and Pharma EBIT at multi‑year highs, but acquisitions flipped net cash to net debt, collapsed OCF, and added loss‑making Med Tech and Consumer units. FY27 re‑rating hinges on OCF recovery, debt reduction, and margin inflection in new segments.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.8% YoY (₹232,415 Mn → ₹271,484 Mn), led by Pharma (₹205,415 Mn → ₹224,121 Mn, +9.1%) and a near-doubling of Consumer Products (₹26,976 Mn → ₹39,540 Mn, +46.6%).
Medical Technologies contributed ₹7,823 Mn in FY26 vs ₹24 Mn in FY25 — full-year impact of an acquired business.
Q4FY26 revenue of ₹75,870 Mn was up 16.2% YoY vs Q4FY25 (₹65,279 Mn), with sequential improvement from Q3FY26 (₹68,645 Mn).

Bottomline

Net profit grew 11.3% YoY (₹45,255 Mn → ₹50,400 Mn); exceptional items of ₹5,166 Mn (vs ₹2,196 Mn in FY25) weighed on reported PAT.
Pre-exceptional PBT rose 14.3% YoY (₹62,463 Mn → ₹71,377 Mn) — underlying earnings quality remains strong.
Effective tax rate dropped meaningfully: 23.4% in FY26 vs 23.4% in FY25 — stable, no distortion from deferred tax movements at the net level.

Margins

EBITDA proxy (PBT before exceptional + D&A + Finance costs): ₹71,377 + ₹14,080 + ₹4,389 = ₹89,846 Mn on revenue of ₹271,484 Mn → EBITDA margin ~33.1% vs ₹62,463 + ₹9,158 + ₹1,699 = ₹73,320 Mn on ₹232,415 Mn → 31.5% in FY25. ~160 bps expansion YoY.
Net profit margin: ₹50,400 / ₹271,484 = 18.6% vs ₹45,255 / ₹232,415 = 19.5% — 90 bps compression, driven by higher D&A (₹14,080 Mn vs ₹9,158 Mn) and finance costs (₹4,389 Mn vs ₹1,699 Mn) post-acquisitions.
Consumer Products EBIT margin compressed sharply: ₹2,671 / ₹39,540 = 6.8% vs ₹3,470 / ₹26,976 = 12.9% — the acquired business is dilutive at EBIT level.

Growth Trajectory

3-year revenue compounding is intact; FY26’s 16.8% growth is above-industry for a company of this scale.
Pharma segment — the core engine — delivered only 9.1% growth; incremental revenue acceleration depended heavily on acquisitions.
Medical Technologies segment is loss-making (EBIT: -₹1,782 Mn) and rapidly scaling costs — trajectory unclear without further disclosure.

SOLARINDS – Solar Industries India – Q4 FY26 Earnings Call – 15-May-26

Solar Industries’topline growth is defense/international-led, margins hinge on commodity pass-through and mix, and bottomline resilience depends on subsidiary execution and working capital normalization.

1–2 minutes

Also see: SOLARINDS – Solar Industries India – Q4 FY26 Financial Results – 15-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Defense hits INR4,500 crores, international grows 25%, and domestic recovers modestly. Commodity lag pressures Q1 margins, but full-year EBITDA holds at 27–28%. Revenue: INR14,000 crores, EPS growth: 10–12%.

TMCV – Tata Motors Limited – Q4 FY26 Earnings Call – 13-May-26

Tata Motors’ topline resilience hinges on diesel/commodity stability and international execution; margins depend on cost discipline and pricing power; FCF remains robust under disciplined capital allocation.

1–2 minutes

Also see: TMCV – Tata Motors Limited (Formerly TML Commercial Vehicles Limited) – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Diesel prices stabilize; commodity inflation moderates in H2 FY27. Single-digit volume growth in Q1 FY27 sustains, with teens EBITDA margins via cost discipline and selective price hikes. Indonesia order deliveries ramp, offsetting MENA/SAARC softness. FCF at 10–12% of revenue; net cash position stable. Iveco deal closes in Q2 FY27, adding strategic depth.

DLF – DLF Limited – Q4 FY26 Earnings Call – 13-May-26

DLF’s base case supports 10–12% topline growth, 15% bottomline expansion, and stable margins, with upside tied to Dahlias and rental NOI, and downside to execution delays and SEZ vacancies.

1–2 minutes

Also see: DLF – DLF Limited – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

FY27 sales hit INR 20,000 crore (Dahlias: INR 5,500 crore; launches: INR 13,500 crore). Rental NOI grows 15% CAGR (INR 8,200 crore exit run-rate). RERA escrow unlocks INR 5,000 crore in FY27, funding dividends (INR 8–9/share) and capex. Topline: +10–12% YoY; Bottomline: +15% (DCCDL-led); Margins: Stable at 39–40%.